Incretin Atlas › Molecules › DD1013
DD1013
GLP-1 + GIP + amylin (triple) · s.c. · Huadong Medicine
Summary
- Also known as
- Huadong
- Mechanism
- GLP-1 + GIP + amylin (triple)
- Route
- s.c.
- Company
- Huadong Medicine
- Highest development stage
- preclinical
- Status (as of data cut)
- Preclinical (EASD 2026) verify
- Next milestone
- Phase 1
Trial arms: weight, HbA1c and tolerability
No trial arms with extracted efficacy or tolerability data yet.
Primary sources
No source recorded.
How to cite this page
Medical Adviser's Group. Incretin Atlas: DD1013. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/dd1013/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.